MedTrace Logo

Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma

NCT01123304 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2014-07-17

No results posted yet for this study

Summary

This research is being done to find out the safety of MORAb-028 in subjects with metastatic melanoma.

Conditions

Interventions

DRUG

MORAb028

1 mg MORAb-028 will be injected at either 1 mg/cm3 per day over 5 days for a total dose of 5 mg for the first cohort and 2 mg/cm3 for the second cohort. Subjects will receive MORAb-028 injections on Days: 1-5, 8-12 and 22-26.

Sponsors & Collaborators

  • Morphotek

    lead INDUSTRY

Principal Investigators

  • Bruce Wallin, MD · Morphotek

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01123304 on ClinicalTrials.gov